Abstract：
BACKGROUND: Liver cirrhosis causes over one million deaths annually worldwide, but its prognosis varies depending on the presence of complications and decompensating events. Reduction of portal pressure is associated with a reduced risk of mortality in cirrhotic patients. Statin therapy has successfully reduced portal pressure in previous studies, but its effects on overall mortality are unclear. This report aims to determine whether statin therapy significantly affects mortality in patients with liver cirrhosis.
METHODS: A comprehensive literature search was conducted using five electronic databases: PubMed, Scopus, Embase, Ovid MEDLINE, and Web of Science. Meta-analyses, randomized controlled trials (RCTs), and cohort studies were selected based on pre-set inclusion and exclusion criteria. The quality of selected studies was evaluated using critical appraisal tools developed by the Center for Evidence-Based Medicine.
RESULTS: One meta-analysis, one RCT, and one retrospective cohort study were included in this report. The meta-analysis and cohort study were of good quality and reported significantly reduced mortality with statin therapy in cirrhosis patients. However, the RCT had poor validity and did not report a statistically significant difference in mortality between the intervention and control groups. The survival benefits of statins may be limited to Child-Pugh A and B patients only, but this requires confirmation in a larger population of Child-Pugh C patients.
CONCLUSIONS: Statins potentially reduce mortality in patients with liver cirrhosis, but more evidence is required before they can be widely recommended in clinical practice for this indication.
METHODS: A comprehensive literature search was conducted using five electronic databases: PubMed, Scopus, Embase, Ovid MEDLINE, and Web of Science. Meta-analyses, randomized controlled trials (RCTs), and cohort studies were selected based on pre-set inclusion and exclusion criteria. The quality of selected studies was evaluated using critical appraisal tools developed by the Center for Evidence-Based Medicine.
RESULTS: One meta-analysis, one RCT, and one retrospective cohort study were included in this report. The meta-analysis and cohort study were of good quality and reported significantly reduced mortality with statin therapy in cirrhosis patients. However, the RCT had poor validity and did not report a statistically significant difference in mortality between the intervention and control groups. The survival benefits of statins may be limited to Child-Pugh A and B patients only, but this requires confirmation in a larger population of Child-Pugh C patients.
CONCLUSIONS: Statins potentially reduce mortality in patients with liver cirrhosis, but more evidence is required before they can be widely recommended in clinical practice for this indication.
摘要：
背景：全世界每年肝硬化导致超过一百万人死亡，但其预后因有无并发症和失代偿事件而异.门静脉压力的降低与肝硬化患者死亡风险的降低相关。他汀类药物治疗在以前的研究中成功地降低了门静脉压力，但其对总死亡率的影响尚不清楚.本报告旨在确定他汀类药物治疗是否显著影响肝硬化患者的死亡率。
方法：使用五个电子数据库进行了全面的文献检索：PubMed，Scopus,Embase,OvidMEDLINE,和WebofScience。荟萃分析，随机对照试验（RCT），根据预先设定的纳入和排除标准选择队列研究.使用循证医学中心开发的关键评估工具评估选定研究的质量。
结果：一项荟萃分析，一个RCT,本报告包括一项回顾性队列研究.荟萃分析和队列研究质量良好，并报道了他汀类药物治疗肝硬化患者的死亡率显着降低。然而,RCT的有效性较差,干预组和对照组的死亡率差异无统计学意义.他汀类药物的生存益处可能仅限于Child-PughA和B患者，但这需要在更多Child-PughC患者中进行确认。
结论：他汀类药物可能降低肝硬化患者的死亡率，但是在临床实践中广泛推荐该适应症之前，还需要更多的证据。
方法：使用五个电子数据库进行了全面的文献检索：PubMed，Scopus,Embase,OvidMEDLINE,和WebofScience。荟萃分析，随机对照试验（RCT），根据预先设定的纳入和排除标准选择队列研究.使用循证医学中心开发的关键评估工具评估选定研究的质量。
结果：一项荟萃分析，一个RCT,本报告包括一项回顾性队列研究.荟萃分析和队列研究质量良好，并报道了他汀类药物治疗肝硬化患者的死亡率显着降低。然而,RCT的有效性较差,干预组和对照组的死亡率差异无统计学意义.他汀类药物的生存益处可能仅限于Child-PughA和B患者，但这需要在更多Child-PughC患者中进行确认。
结论：他汀类药物可能降低肝硬化患者的死亡率，但是在临床实践中广泛推荐该适应症之前，还需要更多的证据。
